• Injection: 250mg, 500mg, 1g

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• 250mg, 500mg & 1g injections 

• Injection: 500/100 (600mg), 1000/200 (1.2g)

• Tablets: 250/125, 500/125
• Oral suspension (sugar-free available): 125/31, 250/62, 400/57

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• 1g and 2g vials
• Approved as an alternative to flucloxacillin in patients with non-immediate penicillin allergy or in those who cannot tolerate flucloxacillin or alternatives
• To be used on the advice of microbiology and ID physicians only.

• 1g powder for concentrate for solution for infusion
  
  • approved for the treatment of infections with gram negative aerobic bacteria in patients with limited treatment options. Only to be used on the advice of microbiology and ID physicians

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
• 200mg tablets
• 100mg in 5ml paediatric suspension: also approved for the prevention of irinotecan induced diarrhoea, specialist use only .

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• Approved for the treatment of hospital acquired pneumonia and other infections on the advice of microbiology/infectious disease physicans.

• Approved for use in multiple antibiotic resistant strains of enterobacteriaceae, pseudomonas and acinetobacters on the advice of microbiology/infectious disease physicians.

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines. 
• Approved for use in primary care (i.e. care homes) to treat patients with conditions such as UTIs and pneumonia, at risk of sepsis in line with local guidance and microbiology input 

• 2.5g injection
• Approved for use only on the advice of Microbiology/Infectious Diseases for the treatment of infections with carbapenemase-producing organisms for which treatment options are very limited, toxic and not particularly effective.

• Imipenem 500 mg,  Cilastatin 500 mg & Relebactam 250 mg powder for solution for infusion
  
  
  
  • Approved for the treatment of multi-resistant gram-negative infections ONLY on the advice of microbiologists
  
  
  
  

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• Meropenem 1 gram / vaborbactam 1 gram. To be used only on advice of microbiology/infectious disease physician

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• To be used in accordance with NHS England Commissioning Policy   

• 50mg and 100mg capsules 


• 100mg/5ml injection   unlicensed
  
  
  
  • approved as sclerosing agent for lymphatic malformations in children
  
  
  
  

• Note: not be prescribed for the treatment of acne in new patients (July 2019). 

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
• Approved for the treatment of non-tuberculous mycobacterial pulmonary diseases caused by Mycobacterium Avium Complex (MAC) that is refractory to current treatment options (adults and post pubescent children) in line with NHSE Specialised Commissioning Policy 

• 80mg in 2ml & 20mg in 2ml IV/IM injections
• 5mg in 1ml intrathecal injection
• bone cement & beads (for use in orthopaedic surgery) unlicensed.

• 500mg tablets
• 1g in 10ml syrup unlicensed.

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
  
  • 80mg in 2ml & 240mg in 6ml injections.
• Inhaled preparations to be used for treatment of Cystic Fibrosis in accordance with NHS England Commissioning Policy/NICE Guidance.
  • 300mg/4ml nebuliser solution ampoules (Bramitob®);
  • 300mg/5ml nebuliser solution ampoules (Tobi®);
  • 170mg/1.7ml nebuliser solution ampoules (Vantobra®);
  • 28mg inhalation powder capsules (Tobi® Podhaler)  

• Approved for
  • For long term therapy in non-cystic fibrosis bronchiectasis usually in patients having > 3 exacerbations per annum with an organism identified as being sensitive to gentamicin.
  • Nebulised therapy for patients on assisted ventilation, patients with tracheostomies and those with persistant bacterial bronchitis 

• Only approved for the treatment of gonorrhoea in adults.

• Injection (for IV infusion): 500mg

• Injection for infusion: 1g vial*

• 500mg powder vial for infusion

• Tablets: 250mg, 500mg
• Capsules: 250mg
• Oral suspension: 200mg/5ml

• 150mg capsules.
• 75mg in 5ml suspension unlicensed

• Injection: 300mg/2ml, 600mg/4ml

• 500mg injection
• approved for the treatment of significant deep soft tissue infections such as joint, discitis and spinal infection, on the advice of infectious disease physicians or microbiology.

• 200mg tablet and 200mg powder for concentrate for solution for infusion
• Approved for thre treatment of bacterial skin and skin structure infections only on the advice of microbiologists/ID physicians

• Tablets: 500 mg

• Approved for
  • Pregnant women infected with Mycoplasma Genitalium (MG) infection that is resistant to macrolides
  • Mycoplasma Genitalium (MG) infection that is resistant to macrolides, quinolones and tetracyclines in both men and women

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• 500mg capsules unlicensed 
• 4g injections 
• 3g sachets: sachets can be initiated in primary care for the treatment of UTIs caused by multi-resistant organisms following advice from microbiology only. Most cost effective option to be used 

• 250mg film coated tablets
• 250mg in 5ml suspension

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• 20mg in 4ml intrathecal injection unlicensed 
• 500mg and 1g injections 

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
  
  • 125mg capsules 

• IV infusion: 600mg/300ml

• Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.

• 600mg tablets
• 100mg in 5ml suspension

To be used only on the advice of a Consultant Microbiologist for resistant Gram-positive infections.

Patients must have weekly bloods taken to monitor for haematological side effects if receiving treatment for more than 10 to 14 days. In those receiving treatment for more than 4 weeks a pre-treatment eye assessment is recommended followed by monthly assessments. Patients should be warned to report any visual symptoms promptly (see BNF for CSM warning).

Linezolid is a MAO inhibitor and so potentially life threatening interactions can occur. Check before prescribing.

• 600mg tablets
• 100mg in 5ml suspension

To be used only on the advice of a Consultant Microbiologist for resistant Gram-positive infections.

RED drug for courses greater than 14 days  

Patients must have weekly bloods taken to monitor for haematological side effects if receiving treatment for more than 10 to 14 days. In those receiving treatment for more than 4 weeks a pre-treatment eye assessment is recommended followed by monthly assessments. Patients should be warned to report any visual symptoms promptly (see BNF for CSM warning).

Linezolid is a MAO inhibitor and so potentially life threatening interactions can occur. Check before prescribing.

• 1 million-unit & 2 million-unit vial for nebulisation/intravenous injection
  
  • Nebulised therapy for bronchiectasis 
  • Nebulised therapy for patients on assisted ventilation, patients with tracheostomies and those with persistant bacterial bronchitis 
  • To be used for treatment of Cystic Fibrosis in accordance with NHS England Commissioning Policy/NICE Guidance.
  • Nebulised therapy for CF .
  • Intravenous therapy .
  • Dry powder for inhalation (Colobreath®) .
    
    

• 550mg Tablets: Only approved for use in accordance with NICE guidance. 

• 200mg tablets
• Fidaxomicin 40mg/ml granules for oral suspension
  • Approved for use in the treatment of C. difficile. To be initiated on the recommendation of a consultant microbiologist.

• 480mg in 5ml ampoules for IV infusion

• 480mg tablets, 960mg tablets
• 240mg in 5ml & 480mg in 5ml suspensions.

• 1g injection

• Infectious diseases, microbiology or respiratory advice only Only in patients with MDR-TB intolerant of other medication

• 250mg capsules Infectious diseases
• microbiology or respiratory advice only

• 50mg in 2ml injection

• 50mg & 100mg tablets
• 50mg in 5ml elixir unlicensed

• 150mg & 300mg capsules 
• 100mg in 5ml syrup 
• 600mg vials for IV infusion   

• To be used in accordance with NHS England Commissioning Policy 

• To be used in accordance with NHS England Commissioning Policy 

• 250mg tablets - Unlicensed

• Infectious diseases, microbiology or respiratory advice only

• 50mg and 100mg capsules
  
  • Approved for the treatment of non-tuberculous mycobacterial (NTM) infections, on the advice of microbiology and Infectious Diseases (ID) physicians

• Used in the treatment of leprosy and some skin conditions (e.g. dermatitis herpetiformis, pemphigoid on the advice of dermatologists).

• 200mg & 400mg tablets 
• 200mg in 5ml suspension 
• 500mg & 1g suppositories 

• 50mg in 10ml injection & 500mg in 100ml IV infusion 

• 100mg & 200mg, 400mg intravenous infusions 

• 450mg tablets

• 300mg powder for concentrate for solution for infusion
  
  
• approved for the treatment of acute bacterial skin and skin structure infections where other antibiotics are inappropriate either due to resistant organisms or intolerance/allergy

• 500mg/100ml infusion 

• 240mg/2.4ml nebuliser solution in line with NHS England Commissioning Policy

• IV infusion: 200mg/100ml 

• Tablets: 200mg, 400mg
• For use in the treatment of pelvic inflammatory disease and chlamydia genital tract infections in accordance with local primary care guidelines.

• 250mg & 500mg tablets 

• Note: Liquid presentations of nitrofurantoin are very expensive compared to
  other solid dosage formulation. Please consider whether capsules can be used.

• Capsules: 50mg, 150mg, 200mg
• Oral solution: 50mg/5ml, 200mg/5ml 

• 100mg capsules 
• 50mg in 5ml oral solution 

• IV infusion: 50mg/25ml, 200mg/100ml

• Approved for use in line with licensed indications and specifically in solid organ transplant and bone marrow transplant recipients.

• 250mg in 25ml injection for IV infusion 

• Approved for the prevention of invasive fungal infection in immunocompromised patients in whom there is a specific risk of aspergillus infection or where fluconazole and itraconazole are not tolerated or are unlikely to be sufficiently effective (largely for secondary prevention).
• Approved for patients with invasive fungal infections that are not responding to other treatments or where they are not tolerated (largely in place of liposomal amphotericin/ voriconazole).

•  for the treatment of non-invasive fungal infections (Off-label indication) using the 100mg tablets ONLY. Can be initiated in primary care on the basis of C&S results / microbiology advice in patients who are not under secondary care.

• 100,000 units/ml suspension .
• 100,000 unit pessaries unlicensed 
  
  • Second line treatment for vaginal non albicans infection, for patients who have not responded to standard treatments such as azoles. Prescribing is restricted to the GUM clinics.
  
  

• 50mg injection (Fungizone®)
• 50mg liposomal injection (Ambisome®)

• For very limited use where terbinafine is contraindicated.

• 500mg tabletsunlicensed.
• 2.5g in 250ml IV infusion.

• Bictegravir (as Bictegravir sodium) 30 mg, Emtricitabine 120 mg, Tenofovir alafenamide (as Tenofovir alafenamide fumarate) 15 mg  &
  Bictegravir (as Bictegravir sodium) 50 mg, Emtricitabine 200 mg, Tenofovir alafenamide (as Tenofovir alafenamide fumarate) 25 mg tablets

• 150 mg and 300 mg tablets
• 50 mg/5ml oral solution

• For limited use as part of triple therapy where other protease inhibitors are unsuitable

To be used in accordance with NHS England Clinical Commissioning Policy (SSC1614).

To be used in accordance with NHS England Clinical Commissioning Policy (SSC1614).

• For patients who, due to renal impairment, require reduced doses that are not able to be accommodated by the fixed combination product.

• 30mg tablet


• 600mg/3ml prolonged-release suspension for injection


• Approved in combination with rilpivirine (Rekambys) for treating HIV-1 in adults in line with NICE

• 600mg MR tablets
• Approved for the treatment of multi-drug resistant HIV-1 infection in adults

• Approved for use in the treatment of patients with HIV infections that are resistant to standard therapy in accordance with British HIV Association and EACS guidelines.

• Approved for use in the treatment of patients with HIV infections that are resistant to standard therapy in accordance with British HIV Association and EACS guidelines.

• Film-coated tablet containing dolutegravir sodium equivalent to 50 mg dolutegravir and 300 mg lamivudine

• Film-coated tablets containing dolutegravir sodium (equivalent to 50 mg dolutegravir) and rilpivirine hydrochloride (equivalent to 25 mg rilpivirine)

• Tablets: Emtricitabine 200 mg and Tenofovir disoproxil (as fumarate) 245 mg

• Use generic preparation in preference to the branded product (Truvada®)

• Tablets: 200 mg / 25 mg / 245 mg

• To be used in accordance with NHS England Clinical Commissioning Policy.

• Tablet: 200mg / 150 mg / 150 mg / 10 mg
• To be used in accordance with NHS England Clinical Commissioning Policy.

• Film coated tablets containing rilpivirine 25mg, emtricitabine 200mg & tenofovir alafenamide (as fumarate) 25mg
• To be used in accordance with NHS England Clinical Commissioning Policy.

• Film coated tablets containing:
  
  • emtricitabine 200mg & tenofovir alafenamide (as fumarate) 10mg
  • emtricitabine 200mg & tenofovir alafenamide (as fumarate) 25mg
• To be used in accordance with NHS England Clinical Commissioning Policy.

• Injection (for IV infusion): 250mg, 500mg

• 125mg, 250mg and 500mg tablets

• Approved for the prevention of cytomegalovirus disease after a stem cell transplant in line with NICE

• 200mg film coated tablets

• For use in the prevention and treatment of cytomegalovirus infection. 
• For limited use by ENT Surgeons in the treatment of selected
  patients with respiratory papillomatosis (unlicensed)

• 10 mg tablets

• Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.  

• Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.

• Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.

• Approved  for hepatitis B and C in accordance with NICE guidelines and NHS England Commissioning Policies. 

• See Section 08.02.04

• Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.

• To be used in accordance with NHS England Commissiong Policy  

• Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.

• Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.

• 2mg powder for solution for injection
• Approved as an option for treating chronic hepatitis D in adults with compensated liver disease in line with NICE and NHSE Specialised Commissioning Policy only if:
  • there is evidence of significant fibrosis (METAVIR stage F2 or above or Ishak stage 3 or above) and
  • their hepatitis has not responded to peginterferon alfa‑2a (PEG‑IFN) or they cannot have interferon-based therapy
• Only available from:
  • The Newcastle Upon Tyne Hospitals NHS Foundation trust

• 30mg, 45mg and 75mg capsules


• 6mg/mL oral suspension


• Only approved for use in accordance with NICE guidance. 

• 5mg inhalation powder blisters with Diskhaler  

• Only approved for use in accordance with NICE guidance. 

• 200mg/20mL solution for infusion
  
  • Approved on the advice of virology/microbiology/ID physician only
  
  
  

• To be used in accordance with NHS England Commissioning Policy.   

• Nirmatrelvir 150mg tablets and Ritonavir 100mg tablets (Paxlovid^®)
• As per NICE TA 878

• 100mg powder for concentrate for solution for infusion
• Approved as an option for treating COVID-10 in hospitals in line with NICE:
  • adults, only if they have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19)
  • babies, children and young people, only if they: 

    • are aged 4 weeks to 17 years and weigh at least 3 kg, and: 

      • have pneumonia, and

      • need supplemental oxygen, or

       

    • weigh at least 40 kg, and have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID‑19).

• 500mg concentrate for solution for infusion

• Molnupiravir (Lagevrio^®) 200mg capsules
• Approved for FOURTH LINE use as per NHS England » Interim clinical commissioning policy: Remdesivir and molnupiravir for non-hospitalised patients with COVID-19

• 250mg tablets and Injection
• For Leishmaniasis
• Infectious diseases of microbiology advice only

• 160mg/20mg & 320mg/40mg tablets
  • Approved for the treatment for plasmodium falciparum malaria in line with current UK and WHO guidelines.
  • Only available from Newcastle Hospitals (RVI)

• Approved for severe malaria in in line WHO guidance.

• 200mg tablets (=150mg chloroquine base)   Not NHS. 
• 68mg in 5ml syrup (=50mg in 5ml chloroquine)   Not NHS
  272.5mg in 5ml injection (=200mg in 5ml chloroquine) unlicensed .

Note: not approved on the NHS for prophylaxis.  

• 500mg tablets
• Last line option for resistant Trichomonas vaginalis
•  unlicensed

• Infectious diseases or microbiology advice only

• See section 05.01.08

• Approved for use in patients intolerant of co-trimoxazole

• 480mg/5ml injection

• Unlicensed Oral formulations - 3mg tablets
• Chronic strongyloides infection; cutaneous larva migrans;

• 50mg tablets
• For roundworm infections.